KLK6

Aliases
  • Bssp
  • HK-6
  • KLK-6
  • KLK6
  • Kallikrein-6
  • Klk7
  • Neurosin
  • PRSS18
  • PRSS9
  • Protease M
  • SP59
  • Serine protease 18
  • Serine protease 9
  • Zyme
  • kallikrein-related peptidase 6
Description
Serine protease M expressed on epithelial cell surface and released in ECM. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis. Overexpressed in primary breast tumors but not expressed in metastatic tumors.
Attributes
QA State
Accepted
Type
Protein
HGNC Name
KLK6
Certifications
  • None
QA State for Breast

 Non-Public Biomarker

Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.

Certifications
  • None
QA State for Ovary
Accepted
Organ-Specific Notes

Amplification of a chromosome 19q region with the entire kallikrein family associated with ovarian cancer.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. KLK6 alone was not a strong predictor.

Supporting Study Data
Intergrated Systems Biology Approach for Ovarian Cancer Biomarker Discovery
Study phase on the ovary: 1

The overall objective is to validate serum protein markers for early diagnosis of ovarian cancer with the ultimate goal being to develop a multiparametric panel consisting of 2-4 novel markers with 10 known markers for phase 3 analysis. In phase 1, we will screen for markers able to pass a threshold of 98% specificity and 30% sensitivity in a cohort of 300 women. Markers that pass phase 1 validation will be investigated in a phase 2 PRoBE cohort with a 98% specificity and 70% sensitivity cut-off. Finally, markers that pass phase 2 validation will be evaluated in EDRN CVC laboratory specimens with a cut-off of > 98% specificity and 90% sensitivity.

View Protocol
Decision rule: No decision rule specified.
PLCO Ovarian Phase III Validation Study
Study phase on the ovary: 3

see objectives

View Protocol
Decision rule: PMID:21372037
SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study
Study phase on the ovary: 3

see objectives

View Protocol
Decision rule: PMID:21372037
Ovary-Specific Protocols
  • No organ-level protocols specified for ovary.
Ovary-Specific Publications
  • No organ-level publications were listed for ovary.
Ovary-Specific Resources
  • No organ-level resources were given for ovary.